Benefit-Risk SIG

The Benefit-Risk SIG was set up at the start of 2012 to help support those involved in this fast evolving area.

The main aims of the SIG are:

• To understand how best to apply Benefit-Risk Methodologies across the Pharmaceutical Industry
• To discuss and make recommendations on key methodological issues
• To share examples of how Benefit-Risk has been used within pharmaceutical companies
• To share external information including new developments around Benefit-Risk

Currently the SIG has subgroups working on:
 
• Literature review
• Points to consider for creating effects tables
• MCDA/SMAA
• Benefit-Risk in the HTA setting (together with the HTA SIG)
• Training
• Bayesian applications in Benefit-Risk
• Benefit-Risk BLOG

If you have an interest in being involved in this SIG or have an interesting case study or experience of carrying out a structured Benefit-Risk assessment to share, please contact Alexander Schacht

email: Schacht_alexander@lilly.com

Our BLOG can be found under www.benefit-risk-assessment.com

Latest News


Show all news

EventsFuture Events


  • Expert Working Group on Confidentiality of Interim Results - Dates: 11 May, 2017

    The PSI/EFSPI expert working group on Confidentiality of Interim Results are planning to meet face to face on 11 May.
  • Estimating Sample Sizes in Clinical Trials - Dates: 28 – 29 Jun, 2017

    The three most important aspects of a clinical trial are: design, design and design. A sample size estimate is just one aspect of a clinical study design. The course describes calculations for sample size estimation in the design of clinical trials. It will be highlighted how the objectives of a clinical trial will impact on sample size calculations. The course is a practical course and all methods will be illustrated with examples and case studies.
Leeds-80x250

Medical Statistician / Senior Medical Statistician

read more...

GSK logo

Director, Statistics

read more...

Astrazeneca

Associate Director, Statistics Team leader - Early Clinical Development

read more...

Astrazeneca

Early Clinical Development – various levels

read more...

LOGO

Biostatistics Head of Department

read more...

Astrazeneca

Principal Statistician – Centralised Statistical Monitoring

read more...

Astrazeneca

Clinical Trial Design Methodology Expert - Statistical Innovation Team

read more...